key: cord-0803150-79n72lmj
authors: Chan, Edward D.; Sharma, Vibhu
title: Does Hypoxia Itself Beget Worsening Hypoxemia in COVID-19?
date: 2021-01-20
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.01.007
sha: f979fd9d59b821f024acff6cd70814a020dc5774
doc_id: 803150
cord_uid: 79n72lmj

nan

To the Editor: Somers et al 1 discussed the possibility that in COVID-19, hypoxia itself may perpetuate further inflammation, pulmonary vasoconstriction, and thrombogenesis as well as possibly induce SARS-CoV-2 replication, resulting in a complex vicious cycle of more hypoxia. We have several comments which we hope will lead to greater discussions.

First, it is important to distinguish "hypoxia" (low oxygen (O 2 ) at the tissue level and not practical to measure) from "hypoxemia" (low O 2 level in the blood). This distinction is important because one may have tissue hypoxia without hypoxemia; e.g., coronary artery occlusion causes hypoxia in the myocardium without necessarily hypoxemia. In this regard, they provided no guidance on how to determine hypoxia in the absence of hypoxemia; e.g., should supplemental O 2 be given if there is elevated lactate or low mixed venous / low central venous O 2 saturation? Based on their hypothesis that tissue hypoxia may induce conditions that beget more hypoxia, are we to infer that they advocate supraphysiologic levels of O 2 (e.g., targeting supraphysiologic PaO 2 or SpO 2 closer to 100%)? In pre-COVID acute respiratory distress syndrome, a meta-analysis of 25 randomized controlled trials of over 16,000 patients showed that a liberal O 2 treatment strategy (median SpO 2 of 96%) was associated with increased mortality during hospitalization, at 30 days, and at "longest follow-up." 2 While a multicenter study comparing liberal O 2 therapy (target SpO 2 ≥ 96%) with a conservative strategy (target SpO 2 88-92%) showed a clinically significant greater mortality at 90 days in the conservative O 2 therapy group, 3 the lower limit of 88% in the conservative O 2 group has J o u r n a l P r e -p r o o f been criticized to be too low. Indeed, a recent, comprehensive analysis indicated that a target SpO 2 in the "Goldilocks" range of 94-98% is a safe compromise. 4 Somers et al 1 also suggested -consistent with their aforementioned line of reasoning -that hyperbaric O 2 therapy be considered for "advanced cases" of COVID-19 pneumonia.

We believe hyperbaric O 2 treatment is likely to be highly impractical, fraught with infection control issues, and potentially harmful. [5] [6] [7] Second, they cited studies showing that a hypoxic environment enhances replication of the hepatitis C virus and herpes viruses and posited that this may be occurring with SARS-CoV-2. 1 Contrary to their examples, hypoxia has been shown to suppress replication of influenza virus and adenovirus. 8, 9 In this regard, expansion of COVID-19 has been observed to be limited in populations that reside at high-altitudes. 10 Third, we infer from their discussion that hypoxic vasoconstriction is a harmful process when in fact it is an adaptive mechanism in the lungs to try to improve the matching of the perfusion to the ventilation; i.e., a teleological explanation is that it is more beneficial for the host if blood is diverted away from the more diseased (hypoxic) parts of the lungs to areas that are less so in an attempt to maximize oxygenation of venous blood. Since COVID-19 exhibits endothelialitis and microthrombosis, 11 these vascular pathologic processes are likely to prevent the occurrence of this salubrious mechanism of hypoxic vasoconstriction.

Edward D. Chan, M.D. Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado National Jewish Health Denver, Colorado University of Colorado Anschutz Medical Campus, Aurora, Colorado

Progressive Hypoxia: A Pivotal Pathophysiologic Mechanism of COVID-19 Pneumonia

Alhazzani W: Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis

Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome

The search for optimal oxygen saturation targets in critically ill patients: Observational data from large ICU databases

Targeting normoxemia in acute respiratory distress syndrome may cause worse short-term outcomes because of oxygen toxicity

Effect of hyperbaric oxygen on murine neutrophil and T-lymphocyte functions

Infection of mice by aerosols of Klebsiella pneumoniae under hyperbaric conditions

Influenza Virus Proliferation in Hypoxic Mice

Virus-host interactions under hypoxia. Microbes Infect

Geographic components of SARS-CoV-2 expansion: a hypothesis

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19